Ratings AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-05-31 EDT			5-day change	1st Jan Change
1,643 ^SEK	+1.08%		-1.76%	+21.39%

06-02	Astra's Enhertu breast cancer trial shows 'unprecedented' results	RE
06-02	Astra's Enhertu delays breast cancer in patients with low HER2 levels	RE

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The firm trades with high earnings multiples: 21.51 times its 2024 earnings per share.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ASTRAZENECA PLC	+21.39%	240B	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.30%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
NOVARTIS AG	+9.78%	210B	B-
ROCHE HOLDING AG	-5.52%	206B	A+
AMGEN INC.	+6.17%	164B	C+
PFIZER, INC.	-0.45%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes